Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SEBASTIAN B HEERSINK

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1376701391
CMS profile
198758
Location
DOTHAN, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$17,775.95

118 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Long term medical supply or device loan $15,495.72 2
Food and Beverage $2,280.23 116

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SEBASTIAN B HEERSINK

NPI 1376701391 · CMS profile ID 198758

Allopathic & Osteopathic Physicians / Ophthalmology

DOTHAN, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1376701391?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SEBASTIAN B HEERSINK, NPI 1376701391, CMS profile ID 198758. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376701391?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SEBASTIAN B HEERSINK, NPI 1376701391, CMS profile ID 198758. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376701391?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SEBASTIAN B HEERSINK, NPI 1376701391, CMS profile ID 198758, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1376701391?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

118 matching records · $17,775.95 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 118 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 118.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alcon Vision LLC $4.9507/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110641405 CMS
Glaukos Corporation $13.3707/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151981764 CMS
Glaukos Corporation $21.3607/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994216 CMS
Glaukos Corporation $7.4507/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994160 CMS
Glaukos Corporation $9.6707/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994172 CMS
Glaukos Corporation $30.6507/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994252 CMS
Glaukos Corporation $11.2407/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994186 CMS
Glaukos Corporation $36.0107/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994266 CMS
Glaukos Corporation $11.7007/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994190 CMS
Glaukos Corporation $30.0207/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994250 CMS
Glaukos Corporation $14.2407/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994198 CMS
Glaukos Corporation $31.9907/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994260 CMS
Tarsus Pharmaceuticals, Inc. $17.8906/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139102435 CMS
Glaukos Corporation $20.5706/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994214 CMS
Glaukos Corporation $29.0506/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994246 CMS
Glaukos Corporation $8.9906/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151981746 CMS
Glaukos Corporation $29.0606/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994248 CMS
Glaukos Corporation $11.3706/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151981756 CMS
Glaukos Corporation $21.8606/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151981770 CMS
Bausch & Lomb Americas Inc. $44.3106/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140446688 CMS
Glaukos Corporation $18.3205/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994204 CMS
Glaukos Corporation $24.9305/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994234 CMS
Glaukos Corporation $15.3105/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994200 CMS
Glaukos Corporation $24.7805/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994232 CMS
Glaukos Corporation $8.4005/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994166 CMS
Glaukos Corporation $20.2105/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994210 CMS
Glaukos Corporation $9.0105/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994170 CMS
Glaukos Corporation $14.0405/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994196 CMS
Nova Eye, Inc. $41.2204/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152554595 CMS
Rayner Intraocular Lenses Limited $26.9604/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1076275344 CMS
Tarsus Pharmaceuticals, Inc. $16.0104/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139102433 CMS
Glaukos Corporation $19.4304/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994208 CMS
Alcon Vision LLC $7.6304/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110641413 CMS
Glaukos Corporation $33.9004/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151993849 CMS
Tarsus Pharmaceuticals, Inc. $17.5103/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139102431 CMS
Glaukos Corporation $20.1303/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151981766 CMS
Glaukos Corporation $13.2003/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151981762 CMS
Glaukos Corporation $11.4303/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151981758 CMS
Glaukos Corporation $32.2203/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994258 CMS
Glaukos Corporation $10.8103/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151981754 CMS
Glaukos Corporation $28.3503/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151981776 CMS
Glaukos Corporation $10.6602/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151981752 CMS
Glaukos Corporation $25.5102/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151981772 CMS
Glaukos Corporation $26.2702/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151981774 CMS
Rayner Intraocular Lenses Limited $18.6702/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1076273954 CMS
Glaukos Corporation $9.8902/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151981750 CMS
Glaukos Corporation $11.6102/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151981760 CMS
Glaukos Corporation $18.7502/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994206 CMS
Glaukos Corporation $28.5302/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994244 CMS
Glaukos Corporation $11.0002/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151994174 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $984.49 30
PY2020 $1,415.10 28
PY2021 $2,570.99 36
PY2022 $4,805.67 40
PY2023 $1,419.46 78
PY2024 $17,775.95 118
PY2025 $4,264.75 152

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,500.00 1
PY2025 Principal investigator $714,266.43 65
PY2024 Principal investigator $695,788.32 84
PY2023 Principal investigator $664,993.31 90
PY2022 Principal investigator $283,326.80 161
PY2021 Principal investigator $602,141.57 480
PY2020 Recipient $3,868.44 1
PY2020 Principal investigator $459,714.70 163
PY2019 Principal investigator $463,210.82 129

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

66 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $12,375.88 12/31/2025 Non-covered Recipient Entity
TRINITY RESEARCH GROUP LLC
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202533279
Principal investigator 1 Glaukos Corporation $9,470.00 12/17/2025 Non-covered Recipient Entity
Trinity Research Group
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250906656
Principal investigator 1 Glaukos Corporation $18,040.00 12/17/2025 Non-covered Recipient Entity
Trinity Research Group
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250906664
Principal investigator 1 Glaukos Corporation $530.00 12/10/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906572
Principal investigator 1 Glaukos Corporation $107,068.20 12/10/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250906596
Principal investigator 1 Glaukos Corporation $2,420.00 12/10/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250906600
Principal investigator 1 Glaukos Corporation $800.00 11/26/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910531
Principal investigator 1 Glaukos Corporation $1,475.00 11/19/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906568
Principal investigator 1 Glaukos Corporation $44,660.00 11/19/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250906593
Principal investigator 1 Glaukos Corporation $26,155.00 11/19/2025 Non-covered Recipient Entity
Trinity Research Group
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250906660
Principal investigator 1 Glaukos Corporation $2,400.00 10/22/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910473
Principal investigator 1 Glaukos Corporation $575.00 10/22/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910507
Principal investigator 1 Glaukos Corporation $2,800.00 10/08/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906566
Principal investigator 1 Glaukos Corporation $91,530.00 10/08/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250906584
Principal investigator 1 Glaukos Corporation $42,630.00 10/08/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250906589
Principal investigator 1 Glaukos Corporation $1,200.00 10/01/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910493
Principal investigator 1 Johnson & Johnson Surgical Vision, Inc. $1,980.00 09/25/2025 Non-covered Recipient Entity
TRINITY RESEARCH GROUP LLC
A Post-market Clinical Study to Collect Safety and Performance Data on Johnson & Johnson Surgical Vision Products No dispute reported 06/30/2026 1174794899
Principal investigator 1 Glaukos Corporation $2,400.00 09/17/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910709
Principal investigator 1 Glaukos Corporation $2,800.00 09/10/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906562
Principal investigator 1 Glaukos Corporation $39,115.00 09/10/2025 Non-covered Recipient Entity
Trinity Research Group
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250906647
Principal investigator 1 Glaukos Corporation $440.00 09/10/2025 Non-covered Recipient Entity
Trinity Research Group
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250906653
Principal investigator 1 Johnson & Johnson Surgical Vision, Inc. $880.00 09/03/2025 Non-covered Recipient Entity
TRINITY RESEARCH GROUP LLC
A Post-market Clinical Study to Collect Safety and Performance Data on Johnson & Johnson Surgical Vision Products No dispute reported 06/30/2026 1174794882
Principal investigator 1 Glaukos Corporation $394.74 08/27/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903927
Principal investigator 1 Glaukos Corporation $14.52 08/13/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250902525
Principal investigator 1 Glaukos Corporation $59.12 08/13/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250902699
Principal investigator 1 Glaukos Corporation $186.30 08/06/2025 Non-covered Recipient Entity
Trinity Research Group
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus No dispute reported 06/30/2026 1250906398
Principal investigator 1 Glaukos Corporation $2,420.00 08/06/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906557
Principal investigator 1 Glaukos Corporation $73,186.52 08/06/2025 Non-covered Recipient Entity
Trinity Research Group
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250906644
Principal investigator 1 Glaukos Corporation $394.74 07/23/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903792
Principal investigator 1 Glaukos Corporation $4.71 07/09/2025 Non-covered Recipient Entity
Amazon.com, Inc.
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus No dispute reported 06/30/2026 1250908960
Principal investigator 1 Glaukos Corporation $5,070.00 07/02/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906554
Principal investigator 1 Glaukos Corporation $74,085.00 07/02/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250906580
Principal investigator 1 Glaukos Corporation $18,345.00 07/02/2025 Non-covered Recipient Entity
Trinity Research Group
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250906639
Recipient Ocular Therapeutix, Inc. $2,500.00 06/30/2025 Covered Recipient Physician A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) No dispute reported 06/30/2026 1250229387
Principal investigator 1 Glaukos Corporation $2,612.57 06/23/2025 Non-covered Recipient Entity
Trinity Research Group
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus No dispute reported 06/30/2026 1250906394
Principal investigator 1 Glaukos Corporation $7,110.00 06/23/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906546
Principal investigator 1 Glaukos Corporation $8,243.96 06/23/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906550
Principal investigator 1 Glaukos Corporation $20,270.00 06/23/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250906577
Principal investigator 1 Glaukos Corporation $850.00 06/23/2025 Non-covered Recipient Entity
Trinity Research Group
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250906635
Principal investigator 1 Glaukos Corporation $17.72 06/18/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903071
Principal investigator 1 Glaukos Corporation $15.88 06/11/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903137
Principal investigator 1 Glaukos Corporation $517.24 06/04/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904056
Principal investigator 1 ABBVIE INC. $3,350.00 06/03/2025 Non-covered Recipient Entity
TRINITY RESEARCH GROUP LLC
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR No dispute reported 06/30/2026 1202489469
Principal investigator 1 Glaukos Corporation $197.37 05/29/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250904170
Principal investigator 1 Glaukos Corporation $197.37 05/29/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250904310
Principal investigator 1 Glaukos Corporation $114.84 05/14/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903349
Principal investigator 1 Glaukos Corporation $394.74 05/14/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250904727
Principal investigator 1 ABBVIE INC. $1,400.00 04/03/2025 Non-covered Recipient Entity
TRINITY RESEARCH GROUP LLC
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR No dispute reported 06/30/2026 1202472857
Principal investigator 1 Glaukos Corporation $517.24 04/02/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904602
Principal investigator 1 Glaukos Corporation $6,810.00 04/02/2025 Non-covered Recipient Entity
Trinity Research Group
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus No dispute reported 06/30/2026 1250906390
Principal investigator 1 Glaukos Corporation $8,505.00 04/02/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906541
Principal investigator 1 Glaukos Corporation $2.66 03/19/2025 Non-covered Recipient Entity
Amazon.com, Inc.
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus No dispute reported 06/30/2026 1250909347
Principal investigator 1 Glaukos Corporation $258.62 03/12/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904495
Principal investigator 1 ABBVIE INC. $3,350.00 03/06/2025 Non-covered Recipient Entity
TRINITY RESEARCH GROUP LLC
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR No dispute reported 06/30/2026 1202458856
Principal investigator 1 Glaukos Corporation $24,239.92 03/05/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906537
Principal investigator 1 Glaukos Corporation $4.67 03/05/2025 Non-covered Recipient Entity
Amazon.com, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250909567
Principal investigator 1 Glaukos Corporation $394.74 02/26/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250905126
Principal investigator 1 Glaukos Corporation $258.62 02/19/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904987
Principal investigator 1 Glaukos Corporation $421.30 02/19/2025 Non-covered Recipient Entity
Commercial Print Management
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250907882
Principal investigator 1 Glaukos Corporation $19,450.00 02/12/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906532
Principal investigator 1 ABBVIE INC. $1,850.00 02/05/2025 Non-covered Recipient Entity
TRINITY RESEARCH GROUP LLC
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR No dispute reported 06/30/2026 1202444930
Principal investigator 1 Glaukos Corporation $258.62 01/29/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904873
Principal investigator 1 Glaukos Corporation $258.62 01/08/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250905559
Principal investigator 1 Glaukos Corporation $3,405.00 01/08/2025 Non-covered Recipient Entity
Trinity Research Group
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus No dispute reported 06/30/2026 1250906385
Principal investigator 1 Glaukos Corporation $11,685.00 01/08/2025 Non-covered Recipient Entity
Trinity Research Group
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906528
Principal investigator 1 ABBVIE INC. $1,400.00 01/02/2025 Non-covered Recipient Entity
TRINITY RESEARCH GROUP LLC
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR No dispute reported 06/30/2026 1202434678